This prevents excessive foaming and preserves peptide integrity
[DOI] [PubMed] [Google Scholar] 4.Wilding J.P.H., Batterham R.L., Calanna S., Davies M., Van Gaal L.F., Lingvay I., McGowan B.M., Rosenstock J., Tran M.T.D., Wadden T.A., et al
Gastrointestinal Side Effects are the predominant category of adverse reactions: Nausea affects approximately 12-24% of diabetes patients and up to 30% of weight management patients, typically most severe during the first few weeks of treatment or following dose increases Diarrhea occurs in 13-17% of diabetes patients and up to 24% of weight management patients Vomiting is reported by 6-10% of diabetes patients and up to 12% of weight management patients, particularly at higher doses Constipation affects 6-11% of diabetes patients and up to 17% of weight management patients Dyspepsia and abdominal pain occur in 6-9% of patients Decreased appetite is common and contributes to the medication's weight loss effects Gastroesophageal reflux disease (GERD) occurs in some patients, particularly at higher doses These gastrointestinal symptoms typically diminish over time as the body adapts to the medication
Both compounds are developed by Eli Lilly, both target GLP-1 and GIP receptors, but Retatrutide adds a third receptor glucagon creating a triple agonist with superior weight loss results in clinical trials
Weekly administration on the same day helps maintain stable therapeutic levels and reinforces the habit of regular dosing
Nevertheless, they recommend that doctors pay closer attention to thyroid function in patients with kidney failure or preexisting thyroid disorders when prescribing tirzepatide for weight loss
